Xiaofeng Wang

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 13

Top Topics

Multidrug Resistant

Acute Heart Failure

Polycystic Kidney Disease

Acinetobacter Baumannii

Top Venues

Antimicrobial agents and chemotherapy

PharmacoEconomics

Current medical research and opinion

This page only lists publications with an associated author ORCID identifier.

Publications

Vijay D Ivaturi, Jogarao V S Gobburu, Bruce Leslie, Xiaofeng Wang, Pravin Jadhav
Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis. Kidney360 5 (7) (2024)
Vijay D Ivaturi, Jogarao V S Gobburu, Bruce Leslie, Xiaofeng Wang, Pravin Jadhav
Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis. Kidney360 5 (7) (2024)
Vijay D Ivaturi, Jogarao V S Gobburu, Bruce Leslie, Xiaofeng Wang, Pravin Jadhav
Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis. Kidney360 5 (7) (2024)
Vijay D Ivaturi, Jogarao V S Gobburu, Bruce Leslie, Xiaofeng Wang, Pravin Jadhav
Urine Osmolality Is a Potential Marker of Longer-term Efficacy of Tolvaptan in ADPKD: A Post-hoc Analysis. Kidney360 (2024)
Vijay D Ivaturi, Jogarao V S Gobburu, Bruce Leslie, Xiaofeng Wang, Pravin Jadhav
Urine Osmolality Is a Potential Marker of Longer-term Efficacy of Tolvaptan in ADPKD: A Post-hoc Analysis. Kidney360 (2024)
Vijay D Ivaturi, Jogarao V S Gobburu, Bruce Leslie, Xiaofeng Wang, Pravin Jadhav
Urine Osmolality Is a Potential Marker of Longer-Term Efficacy of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease: A Post Hoc Analysis. Kidney360 5 (7) (2024)
Jogarao V S Gobburu, Vijay D Ivaturi, Xiaofeng Wang, Susan E Shoaf, Pravin Jadhav, Vicente E Torres
Comparing Effects of Tolvaptan and Instruction to Increase Water Consumption in ADPKD: Post-hoc Analysis of TEMPO 3:4. Kidney360 (2023)
Marjanne A Piena, Natalie Houwing, Carla W Kraan, Xiaofeng Wang, Heidi C Waters, Craig Bennison
Response to Comment on "An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia". PharmacoEconomics 40 (12) (2022)
Yanlin Wang, Xiaofeng Wang, Matthew Harlin, Frank Larsen, Moeen Panni, Murat Yildirim, Jessica-McDonough Madera, Liz Arias, Andy Forbes, Nihal Mustafa, Inez Ruiz-White, Arash Raoufinia
An alternative start regimen with aripiprazole once-monthly in patients with schizophrenia: population pharmacokinetic analysis of a single-day, two-injection start with gluteal and/or deltoid intramuscular injection. Current medical research and opinion 37 (11) (2021)
Tomohiro Sasaki, Elin M Svensson, Xiaofeng Wang, Yanlin Wang, Jeffrey Hafkin, Mats O Karlsson, Suresh Mallikaarjun
Population Pharmacokinetic and Concentration-QTc Analysis of Delamanid in Pediatric Participants with Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy (2021)
Marjanne A Piena, Natalie Houwing, Carla W Kraan, Xiaofeng Wang, Heidi C Waters, Ruth A Duffy, Suresh Mallikaarjun, Craig Bennison
An Integrated Pharmacokinetic-Pharmacodynamic-Pharmacoeconomic Modeling Method to Evaluate Treatments for Adults with Schizophrenia. PharmacoEconomics (2021)
Suresh Mallikaarjun, Moti L Chapagain, Tomohiro Sasaki, Norimitsu Hariguchi, Devyani Deshpande, Shashikant Srivastava, Alexander Berg, Kuniko Hirota, Yusuke Inoue, Makoto Matsumoto, Jeffrey Hafkin, Lawrence Geiter, Xiaofeng Wang, Tawanda Gumbo, Yongge Liu
Cumulative Fraction of Response for Once- and Twice-Daily Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy 65 (1) (2020)
Xiaofeng Wang, Suresh Mallikaarjun, Ekaterina Gibiansky
Population Pharmacokinetic Analysis of Delamanid in Patients with Pulmonary Multidrug-Resistant Tuberculosis. Antimicrobial agents and chemotherapy 65 (1) (2020)